Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Adenosine 2A Receptor Activation Attenuates Ischemia Reperfusion Injury During Extracorporeal Cardiopulmonary Resuscitation.

Mehaffey JH, Money D, Charles EJ, Schubert S, Piñeros AF, Wu D, Bontha SV, Hawkins R, Teman NR, Laubach VE, Mas VR, Tribble CG, Maluf DG, Sharma AK, Yang Z, Kron IL, Roeser ME.

Ann Surg. 2019 Jun;269(6):1176-1183. doi: 10.1097/SLA.0000000000002685.

PMID:
31082918
2.

Ex Situ Liver Machine Perfusion As An Emerging Graft Protective Strategy In Clinical Liver Transplantation: The Dawn of A New Era.

Nickkholgh A, Nikdad M, Shafie S, Dezfouli SA, Mehrabi A, Eason JD, Mas VR, Maluf DG.

Transplantation. 2019 Apr 22. doi: 10.1097/TP.0000000000002772. [Epub ahead of print]

PMID:
31022148
3.

In utero cell transplantation as a tool for fixing liver-based inherited metabolic disorders: Early technical evidence supporting potential feasibility.

Mas VR, Maluf DG.

Transplantation. 2019 Apr 1. doi: 10.1097/TP.0000000000002736. [Epub ahead of print] No abstract available.

PMID:
30946216
4.

What Is Hot and New in Basic Science in Liver Transplantation in 2018? Report of the Basic Science Committee of the International Liver Transplantation Society.

Martins PN, Selzner M, Dayangac M, Ling Q, Ng KT, Huang KT, Taner T, Mas VR, Ekser B.

Transplantation. 2019 Apr;103(4):654-659. doi: 10.1097/TP.0000000000002617. No abstract available.

PMID:
30801512
5.

Human mesenchymal stromal cell-derived extracellular vesicles attenuate aortic aneurysm formation and macrophage activation via microRNA-147.

Spinosa M, Lu G, Su G, Bontha SV, Gehrau R, Salmon MD, Smith JR, Weiss ML, Mas VR, Upchurch GR Jr, Sharma AK.

FASEB J. 2018 May 29:fj201701138RR. doi: 10.1096/fj.201701138RR. [Epub ahead of print]

PMID:
29812968
6.

Messengers of tolerance.

Bontha SV, Fernandez-Piñeros A, Maluf DG, Mas VR.

Hum Immunol. 2018 May;79(5):362-372. doi: 10.1016/j.humimm.2018.01.008. Epub 2018 Feb 2. Review.

PMID:
29402484
7.

Adenosine 2A Receptor Activation Attenuates Ischemia Reperfusion Injury During Extracorporeal Cardiopulmonary Resuscitation.

Mehaffey JH, Money D, Charles EJ, Schubert S, Piñeros AF, Wu D, Bontha SV, Hawkins R, Teman NR, Laubach VE, Mas VR, Tribble CG, Maluf DG, Sharma AK, Yang Z, Kron IL, Roeser ME.

Ann Surg. 2018 Jan 25. doi: 10.1097/SLA.0000000000002685. [Epub ahead of print]

PMID:
29373368
8.

Intragraft Molecular Pathways Associated with Tolerance Induction in Renal Transplantation.

Gallon L, Mathew JM, Bontha SV, Dumur CI, Dalal P, Nadimpalli L, Maluf DG, Shetty AA, Ildstad ST, Leventhal JR, Mas VR.

J Am Soc Nephrol. 2018 Feb;29(2):423-433. doi: 10.1681/ASN.2017030348. Epub 2017 Nov 30.

9.

Effects of DNA Methylation on Progression to Interstitial Fibrosis and Tubular Atrophy in Renal Allograft Biopsies: A Multi-Omics Approach.

Bontha SV, Maluf DG, Archer KJ, Dumur CI, Dozmorov MG, King AL, Akalin E, Mueller TF, Gallon L, Mas VR.

Am J Transplant. 2017 Dec;17(12):3060-3075. doi: 10.1111/ajt.14372. Epub 2017 Jul 8.

10.

Cellular and molecular profiling of graft injury post renal transplantation.

Mas VR, Maluf DG.

Curr Opin Organ Transplant. 2017 Feb;22(1):36-45. doi: 10.1097/MOT.0000000000000377. Review.

PMID:
27941467
11.

Systems Biology in Kidney Transplantation: The Application of Multi-Omics to a Complex Model.

Bontha SV, Maluf DG, Mueller TF, Mas VR.

Am J Transplant. 2017 Jan;17(1):11-21. doi: 10.1111/ajt.13881. Epub 2016 Jul 12. Review.

12.

Biomarkers of Transplant Tolerance: A Provisional Analysis for an Unmet Need.

Mas VR, Portilla D, Maluf DG.

Transplantation. 2016 Apr;100(4):705-6. doi: 10.1097/TP.0000000000001106. No abstract available.

PMID:
26950715
13.

Hidden Inflammatory Molecular Signatures in Graft Kidney Biopsies: Silent Markers of Graft Fate?

Maluf DG, Mueller TF, Mas VR.

Am J Transplant. 2016 Jul;16(7):1947-8. doi: 10.1111/ajt.13754. Epub 2016 Mar 15. No abstract available.

14.

Epigenetics in Kidney Transplantation: Current Evidence, Predictions, and Future Research Directions.

Mas VR, Le TH, Maluf DG.

Transplantation. 2016 Jan;100(1):23-38. doi: 10.1097/TP.0000000000000878. Review.

PMID:
26356174
15.

Ischemia/reperfusion, does temperature matter? Laboratory perspective.

Mas VR.

Liver Transpl. 2015 Nov;21 Suppl 1:S1-5. doi: 10.1002/lt.24322. Review. No abstract available.

16.

Donor Hepatic Steatosis Induce Exacerbated Ischemia-Reperfusion Injury Through Activation of Innate Immune Response Molecular Pathways.

Gehrau RC, Mas VR, Dumur CI, Suh JL, Sharma AK, Cathro HP, Maluf DG.

Transplantation. 2015 Dec;99(12):2523-33. doi: 10.1097/TP.0000000000000857.

17.

Ex Vivo Perfusion With Adenosine A2A Receptor Agonist Enhances Rehabilitation of Murine Donor Lungs After Circulatory Death.

Stone ML, Sharma AK, Mas VR, Gehrau RC, Mulloy DP, Zhao Y, Lau CL, Kron IL, Huerter ME, Laubach VE.

Transplantation. 2015 Dec;99(12):2494-503. doi: 10.1097/TP.0000000000000830.

18.

A step closer to individualization of hepatocellular carcinoma therapy.

Maluf DG, Mas VR.

J Vasc Interv Radiol. 2015 May;26(5):733-4. doi: 10.1016/j.jvir.2015.01.034. No abstract available.

PMID:
25921455
19.

Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.

Tomlinson JA, Caplin B, Boruc O, Bruce-Cobbold C, Cutillas P, Dormann D, Faull P, Grossman RC, Khadayate S, Mas VR, Nitsch DD, Wang Z, Norman JT, Wilcox CS, Wheeler DC, Leiper J.

J Am Soc Nephrol. 2015 Dec;26(12):3045-59. doi: 10.1681/ASN.2014030280. Epub 2015 Apr 8.

20.

Genetic inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylation.

Chow JD, Lawrence RT, Healy ME, Dominy JE, Liao JA, Breen DS, Byrne FL, Kenwood BM, Lackner C, Okutsu S, Mas VR, Caldwell SH, Tomsig JL, Cooney GJ, Puigserver PB, Turner N, James DE, Villén J, Hoehn KL.

Mol Metab. 2014 Mar 12;3(4):419-31. doi: 10.1016/j.molmet.2014.02.004. eCollection 2014 Jul.

21.

Evaluation of molecular profiles in calcineurin inhibitor toxicity post-kidney transplant: input to chronic allograft dysfunction.

Maluf DG, Dumur CI, Suh JL, Lee JK, Cathro EP, King AL, Gallon L, Brayman KL, Mas VR.

Am J Transplant. 2014 May;14(5):1152-1163. doi: 10.1111/ajt.12696. Epub 2014 Apr 2.

22.

Liver transplant complications in hepatitis C infected recipients: recurrence versus rejection.

Gehrau RC, Mas VR, Suh JL, Maluf DG.

Expert Rev Gastroenterol Hepatol. 2014 Jul;8(5):453-6. doi: 10.1586/17474124.2014.898562. Epub 2014 Mar 18.

PMID:
24641719
23.

The urine microRNA profile may help monitor post-transplant renal graft function.

Maluf DG, Dumur CI, Suh JL, Scian MJ, King AL, Cathro H, Lee JK, Gehrau RC, Brayman KL, Gallon L, Mas VR.

Kidney Int. 2014 Feb;85(2):439-49. doi: 10.1038/ki.2013.338. Epub 2013 Sep 11.

24.

Regulation of molecular pathways in ischemia-reperfusion injury after liver transplantation.

Gehrau RC, Mas VR, Dumur CI, Ladie DE, Suh JL, Luebbert S, Maluf DG.

Transplantation. 2013 Nov 27;96(10):926-34. doi: 10.1097/TP.0b013e3182a20398.

25.

Hepatic disease biomarkers and liver transplantation: what is the potential utility of microRNAs?

Gehrau RC, Mas VR, Maluf DG.

Expert Rev Gastroenterol Hepatol. 2013 Feb;7(2):157-70. doi: 10.1586/egh.12.71. Review.

PMID:
23363264
26.

MicroRNA signature at the time of clinical HCV recurrence associates with aggressive fibrosis progression post-liver transplantation.

Gehrau RC, Mas VR, Villamil FG, Dumur CI, Mehta NK, Suh JL, Maluf DG.

Am J Transplant. 2013 Mar;13(3):729-37. doi: 10.1111/ajt.12047. Epub 2013 Jan 11.

27.

MiRNAs in kidney transplantation: potential role as new biomarkers.

Scian MJ, Maluf DG, Mas VR.

Expert Rev Mol Diagn. 2013 Jan;13(1):93-104. doi: 10.1586/erm.12.131. Review.

PMID:
23256706
28.

MicroRNAs as biomarkers in solid organ transplantation.

Mas VR, Dumur CI, Scian MJ, Gehrau RC, Maluf DG.

Am J Transplant. 2013 Jan;13(1):11-9. doi: 10.1111/j.1600-6143.2012.04313.x. Epub 2012 Nov 8. Review.

29.

Identification of biomarkers to assess organ quality and predict posttransplantation outcomes.

Scian MJ, Maluf DG, Archer KJ, Turner SD, Suh JL, David KG, King AL, Posner MP, Brayman KL, Mas VR.

Transplantation. 2012 Oct 27;94(8):851-8. doi: 10.1097/TP.0b013e318263702b.

30.

Microarray applications in nephrology with special focus on transplantation.

Mueller TF, Mas VR.

J Nephrol. 2012 Sep-Oct;25(5):589-602. doi: 10.5301/jn.5000205. Review.

PMID:
22972670
31.

Molecular profiles of HCV cirrhotic tissues derived in a panel of markers with clinical utility for hepatocellular carcinoma surveillance.

Gehrau RC, Archer KJ, Mas VR, Maluf DG.

PLoS One. 2012;7(7):e40275. doi: 10.1371/journal.pone.0040275. Epub 2012 Jul 5.

32.

Reduced expression of inflammatory genes in deceased donor kidneys undergoing pulsatile pump preservation.

Mas VR, Archer KJ, Dumur CI, Scian MJ, Suh JL, King AL, Wardius ME, Straub JA, Posner MP, Brayman K, Maluf DG.

PLoS One. 2012;7(4):e35526. doi: 10.1371/journal.pone.0035526. Epub 2012 Apr 24.

33.

Pretransplant transcriptome profiles identify among kidneys with delayed graft function those with poorer quality and outcome.

Mas VR, Scian MJ, Archer KJ, Suh JL, David KG, Ren Q, Gehr TW, King AL, Posner MP, Mueller TF, Maluf DG.

Mol Med. 2011;17(11-12):1311-22. doi: 10.2119/molmed.2011.00159. Epub 2011 Sep 6.

34.

Identifying biomarkers as diagnostic tools in kidney transplantation.

Mas VR, Mueller TF, Archer KJ, Maluf DG.

Expert Rev Mol Diagn. 2011 Mar;11(2):183-96. doi: 10.1586/erm.10.119.

35.

Distinctive gene expression profiles characterize donor biopsies from HCV-positive kidney donors.

Mas VR, Archer KJ, Suh L, Scian M, Posner MP, Maluf DG.

Transplantation. 2010 Dec 15;90(11):1172-9. doi: 10.1097/TP.0b013e3181f9ca6c.

PMID:
20935597
36.

Kidney grafts from HCV-positive donors: advantages and disadvantages.

Maluf DG, Archer KJ, Mas VR.

Transplant Proc. 2010 Sep;42(7):2436-46. doi: 10.1016/j.transproceed.2010.04.056.

PMID:
20832522
37.

Identifying genes progressively silenced in preneoplastic and neoplastic liver tissues.

Archer KJ, Zhao Z, Guennel T, Maluf DG, Fisher RA, Mas VR.

Int J Comput Biol Drug Des. 2010;3(1):52-67. doi: 10.1504/IJCBDD.2010.034499. Epub 2010 Aug 5.

38.

Molecular mechanisms involved in the interaction effects of alcohol and hepatitis C virus in liver cirrhosis.

Mas VR, Fassnacht R, Archer KJ, Maluf D.

Mol Med. 2010 Jul-Aug;16(7-8):287-97. doi: 10.2119/molmed.2009.00165. Epub 2010 Mar 26.

39.

Molecular pathways involved in loss of graft function in kidney transplant recipients.

Mas VR, Archer KJ, Scian M, Maluf DG.

Expert Rev Mol Diagn. 2010 Apr;10(3):269-84. doi: 10.1586/erm.10.6. Review.

PMID:
20370585
40.

High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma.

Archer KJ, Mas VR, Maluf DG, Fisher RA.

Mol Genet Genomics. 2010 Apr;283(4):341-9. doi: 10.1007/s00438-010-0522-y. Epub 2010 Feb 18.

41.

Identifying genes for establishing a multigenic test for hepatocellular carcinoma surveillance in hepatitis C virus-positive cirrhotic patients.

Archer KJ, Mas VR, David K, Maluf DG, Bornstein K, Fisher RA.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2929-32. doi: 10.1158/1055-9965.EPI-09-0767. Epub 2009 Oct 27.

42.
43.

Proteomics and liver fibrosis: identifying markers of fibrogenesis.

Mas VR, Fisher RA, Archer KJ, Maluf DG.

Expert Rev Proteomics. 2009 Aug;6(4):421-31. doi: 10.1586/epr.09.59. Review.

PMID:
19681677
44.

Quality assessment of microarray data in a multicenter study.

Archer KJ, Mas VR, O'Brien TR, Pfeiffer R, Lum NL, Fisher RA.

Diagn Mol Pathol. 2009 Mar;18(1):34-43. doi: 10.1097/PDM.0b013e3181731e14.

45.

Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation.

Mas VR, Maluf DG, Archer KJ, Yanek K, Bornstein K, Fisher RA.

Transplantation. 2009 Jan 15;87(1):143-52. doi: 10.1097/TP.0b013e318191c68d.

46.

Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma.

Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, Freise CE, Olthoff KM, Ghobrial RM, McIver P, Fisher R.

Mol Med. 2009 Mar-Apr;15(3-4):85-94. doi: 10.2119/molmed.2008.00110. Epub 2008 Dec 15.

47.

Cell transplant techniques: engraftment detection of cells.

Fisher RA, Mas VR.

Methods Mol Biol. 2009;481:97-105. doi: 10.1007/978-1-59745-201-4_9. Review.

PMID:
19096790
48.

Gene expression patterns in deceased donor kidneys developing delayed graft function after kidney transplantation.

Mas VR, Archer KJ, Yanek K, Dumur CI, Capparuccini MI, Mangino MJ, King A, Gibney EM, Fisher R, Posner M, Maluf D.

Transplantation. 2008 Feb 27;85(4):626-35. doi: 10.1097/TP.0b013e318165491f.

PMID:
18347543
49.

Molecular pathways involved in loss of kidney graft function with tubular atrophy and interstitial fibrosis.

Maluf DG, Mas VR, Archer KJ, Yanek K, Gibney EM, King AL, Cotterell A, Fisher RA, Posner MP.

Mol Med. 2008 May-Jun;14(5-6):276-85. doi: 10.2119/2007-00111.Maluf.

50.

Supplemental Content

Support Center